A test that costs less than a $1 and yields results in minutes has been shown in newly published studies to be more sensitive and more exact than the current standard test for early-stage prostate cancer.
The simple test developed by University of Central Florida scientist Qun “Treen” Huo holds the promise of earlier detection of one of the deadliest cancers among men. It would also reduce the number of unnecessary and invasive biopsies stemming from the less precise PSA test that’s now used.
“It’s fantastic,” said Dr. Inoel Rivera, a urologic oncologist at Florida Hospital Cancer Institute, which collaborated with Huo on the recent pilot studies. “It’s a simple test. It’s much better than the test we have right now, which is the PSA, and it’s cost-effective.”
When a cancerous tumor begins to develop, the body mobilizes to produce antibodies. Huo’s test detects that immune response using gold nanoparticles about 10,000 times smaller than a freckle.
When a few drops of blood serum from a finger prick are mixed with the gold nanoparticles, certain cancer biomarkers cling to the surface of the tiny particles, increasing their size and causing them to clump together.
Among researchers, gold nanoparticles are known for their extraordinary efficiency at absorbing and scattering light. Huo and her team at UCF’s NanoScience Technology Center developed a technique known as nanoparticle-enabled dynamic light scattering assay (NanoDLSay) to measure the size of the particles by analyzing the light they throw off. That size reveals whether a patient has prostate cancer and how advanced it may be.
And although it uses gold, the test is cheap. A small bottle of nanoparticles suspended in water costs about $250, and contains enough for about 2,500 tests.
“What’s different and unique about our technique is it’s a very simple process, and the material required for the test is less than $1,” Huo said. “And because it’s low-cost, we’re hoping most people can have this test in their doctor’s office. If we can catch this cancer in its early stages, the impact is going to be big.”
The Latest on: Prostate Cancer
via Google News
The Latest on: Prostate Cancer
- Gary Lineker reveals cancer scare and urges other men to have regular prostate checkson November 28, 2020 at 2:43 am
Football legend and TV presenter Gary Lineker has revealed he had a cancer scare and urged other men to get regular check-ups from their doctor. The former England goalscorer told of the experience ...
- Al Roker co-hosts Thanksgiving Day parade after prostate cancer surgeryon November 26, 2020 at 9:50 am
Al Roker joined his “Today” show colleagues on Thursday to help co-host Macy’s Thanksgiving Day Parade, following his prostate cancer surgery earlier this month. Taking to Instagram, 66-year-old Roker ...
- Prostate cancer: Pain in testicles could indicate the cancer has spreadon November 26, 2020 at 8:55 am
PROSTATE cancer is the most common cancer in men in the UK, with around 40,000 men diagnosed with prostate cancer every year in England alone. Symptoms can take years to surface and sadly when they do ...
- Bill Turnbull, 64, emotionally urges men to get prostate exams amid his terminal cancer battleon November 26, 2020 at 4:22 am
Bill Turnbull has emotionally urged men to go for prostate exams amid his battle with terminal cancer. The broadcaster, 64, who was diagnosed with incurable prostate cancer in 2017, spoke to Gethin ...
- Insights on the Prostate Cancer Global Market to 2024 - Featuring Pfizer and Bayer Among Otherson November 25, 2020 at 4:47 am
The "Global Prostate Cancer Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering. This report provides a detailed analysis ...
- RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDAon November 24, 2020 at 10:56 pm
RhoVac, a clinical stage company today announced that the American FDA has granted Fast Track Designation to the company's drug ...
- Medical mistrust can make African Americans to regret their choice of treatment for prostate canceron November 24, 2020 at 9:57 pm
Medical mistrust is one reason why African American patients are more likely to have regrets about their choice of treatment for prostate cancer.
- For African American men with prostate cancer, decision regret linked to medical mistruston November 24, 2020 at 12:43 pm
Medical mistrust is one reason why African American patients are more likely to have regrets about their choice of treatment for prostate cancer, suggests a study in The Journal of Urology, Official ...
- Genetic Signature Could Predict Prostate Cancer Metastasison November 24, 2020 at 7:03 am
The discovery of a genetic signature that correlates with metastasis in prostate cancer could make it much easier for physicians and patients to choose treatment strategies.
- Rapid Rise in Cases of Prostate Cancer Worldwide to Influence Growth of Prostate Cancer Therapeutics Market to a Great Extent: TMRon November 24, 2020 at 5:30 am
The prevalence of prostate cancer is magnifying across the world at a rapid rate. According to the estimates by the American Cancer ...
via Bing News